KR101664915B1 - 중독 치료를 위한 화합물 - Google Patents

중독 치료를 위한 화합물 Download PDF

Info

Publication number
KR101664915B1
KR101664915B1 KR1020147002302A KR20147002302A KR101664915B1 KR 101664915 B1 KR101664915 B1 KR 101664915B1 KR 1020147002302 A KR1020147002302 A KR 1020147002302A KR 20147002302 A KR20147002302 A KR 20147002302A KR 101664915 B1 KR101664915 B1 KR 101664915B1
Authority
KR
South Korea
Prior art keywords
compound
oxo
alkyl
benzyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147002302A
Other languages
English (en)
Korean (ko)
Other versions
KR20140042884A (ko
Inventor
카리나 이 카니자로
미하엘 그라우페
후안 에이 게레로
야판 루
로버트 지 스트릭리
찬드라세카르 벤카타라마니
제프 자블로키
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20140042884A publication Critical patent/KR20140042884A/ko
Application granted granted Critical
Publication of KR101664915B1 publication Critical patent/KR101664915B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147002302A 2011-07-01 2012-06-29 중독 치료를 위한 화합물 Expired - Fee Related KR101664915B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503923P 2011-07-01 2011-07-01
US61/503,923 2011-07-01
PCT/US2012/044809 WO2013006400A1 (en) 2011-07-01 2012-06-29 Compounds for the treatment of addiction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023967A Division KR20160106207A (ko) 2011-07-01 2012-06-29 중독 치료를 위한 화합물

Publications (2)

Publication Number Publication Date
KR20140042884A KR20140042884A (ko) 2014-04-07
KR101664915B1 true KR101664915B1 (ko) 2016-10-11

Family

ID=46513858

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167023967A Withdrawn KR20160106207A (ko) 2011-07-01 2012-06-29 중독 치료를 위한 화합물
KR1020147002302A Expired - Fee Related KR101664915B1 (ko) 2011-07-01 2012-06-29 중독 치료를 위한 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020167023967A Withdrawn KR20160106207A (ko) 2011-07-01 2012-06-29 중독 치료를 위한 화합물

Country Status (32)

Country Link
US (6) US8558001B2 (enExample)
EP (2) EP2726460B1 (enExample)
JP (1) JP5943998B2 (enExample)
KR (2) KR20160106207A (enExample)
CN (1) CN103635460B (enExample)
AP (1) AP3544A (enExample)
AR (1) AR086792A1 (enExample)
AU (1) AU2012279332B2 (enExample)
BR (1) BR112014000033A2 (enExample)
CA (1) CA2840763C (enExample)
CL (1) CL2013003597A1 (enExample)
CO (1) CO6821964A2 (enExample)
CR (1) CR20130659A (enExample)
DK (1) DK2993170T3 (enExample)
EA (1) EA025573B1 (enExample)
EC (1) ECSP13013087A (enExample)
ES (2) ES2656716T3 (enExample)
IL (1) IL230657B (enExample)
MA (1) MA35404B1 (enExample)
MD (1) MD4436B1 (enExample)
MX (1) MX337611B (enExample)
PE (1) PE20141067A1 (enExample)
PH (1) PH12013502674A1 (enExample)
PL (1) PL2726460T3 (enExample)
PT (1) PT2726460E (enExample)
SG (1) SG10201605355RA (enExample)
SI (1) SI2726460T1 (enExample)
TW (1) TWI567061B (enExample)
UA (1) UA109199C2 (enExample)
UY (1) UY34165A (enExample)
WO (1) WO2013006400A1 (enExample)
ZA (1) ZA201308977B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN105693645B (zh) 2011-05-10 2018-10-09 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
SI3080134T1 (sl) * 2013-12-13 2018-11-30 Vertex Pharmaceuticals Incorporated Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov
US10077669B2 (en) 2014-11-26 2018-09-18 United Technologies Corporation Non-metallic engine case inlet compression seal for a gas turbine engine
US10289971B2 (en) 2015-02-13 2019-05-14 Atlassian Pty Ltd Issue and trigger rebalancing in a ranked issue management system
ES2935204T3 (es) * 2016-08-19 2023-03-02 Univ Bristol Derivados de citisina para el tratamiento de la adicción
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019079209A1 (en) * 2017-10-16 2019-04-25 Amygdala Neurosciences, Inc. POLYTHERAPY FOR THE PREVENTION OF AN ADDICTION
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019222112A1 (en) 2018-05-14 2019-11-21 Gilead Sciences, Inc. Mcl-1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
EP3829562A1 (en) * 2018-07-27 2021-06-09 Amygdala Neurosciences, Inc. Combination therapy for nicotine addiction
EP3863424A4 (en) * 2018-10-12 2022-08-03 Amygdala Neurosciences, Inc. ADDICTION TREATMENT OF AN ALCOHOLIC PATIENT POPULATION
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
EP4540228A1 (en) 2022-06-14 2025-04-23 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
JP2025520426A (ja) 2022-06-14 2025-07-03 アミグダラ ニューロサイエンシーズ， インコーポレイテッド Ａｌｄｈ－２阻害化合物及び使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP1077697B1 (en) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
KR20060011785A (ko) * 2002-06-27 2006-02-03 디 인다우먼트 포 리써치 인 휴먼 바이올로지, 인크. Ａｌｄｈ 억제에 유용한 화합물
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
US20080207610A1 (en) 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
RU2008151762A (ru) * 2006-07-27 2010-06-27 Си Ви Терапьютикс, Инк. (Us) Adlh-2 ингибиторы для лечения аддикции
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
AU2008348372A1 (en) 2008-01-24 2009-07-30 Gilead Palo Alto, Inc. ALDH-2 inhibitors in the treatment of addiction
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof

Also Published As

Publication number Publication date
CA2840763C (en) 2019-09-10
US9610299B2 (en) 2017-04-04
CN103635460B (zh) 2016-03-16
US10507215B2 (en) 2019-12-17
EP2993170B1 (en) 2017-10-25
PL2726460T3 (pl) 2016-03-31
US20180338989A1 (en) 2018-11-29
UA109199C2 (uk) 2015-07-27
HK1197236A1 (en) 2015-01-09
ECSP13013087A (es) 2014-01-31
AP2013007282A0 (en) 2013-11-30
ES2656716T3 (es) 2018-02-28
US20140051668A1 (en) 2014-02-20
ZA201308977B (en) 2014-08-27
PE20141067A1 (es) 2014-09-05
KR20140042884A (ko) 2014-04-07
MA35404B1 (fr) 2014-09-01
EA201391635A1 (ru) 2014-04-30
AR086792A1 (es) 2014-01-22
US9987295B2 (en) 2018-06-05
CN103635460A (zh) 2014-03-12
US20130203704A1 (en) 2013-08-08
US9000015B2 (en) 2015-04-07
CO6821964A2 (es) 2013-12-31
AP3544A (en) 2016-01-14
IL230657A0 (en) 2014-03-31
EA025573B1 (ru) 2017-01-30
CA2840763A1 (en) 2013-01-10
HK1217487A1 (en) 2017-01-13
WO2013006400A1 (en) 2013-01-10
MD4436B1 (ro) 2016-09-30
CR20130659A (es) 2014-02-18
KR20160106207A (ko) 2016-09-09
JP5943998B2 (ja) 2016-07-05
NZ618537A (en) 2016-03-31
US8575353B2 (en) 2013-11-05
MX337611B (es) 2016-03-10
IL230657B (en) 2018-02-28
DK2993170T3 (da) 2018-01-29
UY34165A (es) 2013-01-31
US8558001B2 (en) 2013-10-15
MX2013014938A (es) 2014-04-30
US20130005689A1 (en) 2013-01-03
TWI567061B (zh) 2017-01-21
CL2013003597A1 (es) 2014-06-13
BR112014000033A2 (pt) 2019-06-18
EP2993170A1 (en) 2016-03-09
AU2012279332B2 (en) 2015-02-05
JP2014520809A (ja) 2014-08-25
SI2726460T1 (sl) 2015-11-30
SG10201605355RA (en) 2016-08-30
US20170266210A1 (en) 2017-09-21
TW201307288A (zh) 2013-02-16
PH12013502674A1 (en) 2014-02-10
EP2726460A1 (en) 2014-05-07
PT2726460E (pt) 2015-12-07
MD20140009A2 (ro) 2014-06-30
ES2553829T3 (es) 2015-12-14
AU2012279332A1 (en) 2013-04-04
US20150250805A1 (en) 2015-09-10
EP2726460B1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
KR101664915B1 (ko) 중독 치료를 위한 화합물
US7951813B2 (en) Quinazolinone derivatives as ALDH-2 inhibitors
EP3863424A1 (en) Addiction treatment of an alcohol-consuming patient population
KR20140057634A (ko) 중독 치료에서의 ａｌｄｈ-2 저해제
EP3829562A1 (en) Combination therapy for nicotine addiction
HK1217487B (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction
NZ618537B2 (en) Mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors
AU2015202264A1 (en) Compounds for the treatment of addiction
AU2016244324A1 (en) Compounds for the treatment of addiction
EP4504340A1 (en) Prodrugs of opicapone
OA16801A (en) Compounds for the treatment of addiction.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190925

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221006

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221006

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000